Principle 1: One at a time
Start each peptide solo for at least two weeks before adding another. You need to know what each one does to you, individually.
If you start three compounds simultaneously and feel terrible, you will not know which one to stop.
This was Module 5's lesson and it reappears here as the first stacking principle, because stacking without it is not stacking. It is a mixture.
Principle 2: Non-overlapping mechanisms only
The logic of stacking is that each compound addresses a different system.
Recovery (BPC-157) + Sleep (DSIP) = different targets. Defensible.
Two growth-promoting peptides = overlapping risk. Not defensible.
This is why the categories in Module 1 matter operationally. Two GHRH analogs is one mechanism twice. GHRP-6 with GHRP-2 is one receptor twice. Semaglutide with tirzepatide is one incretin pathway twice.
The pairing that works, tesamorelin with ipamorelin, works precisely because it is a GHRH receptor plus a ghrelin receptor. Two doors into the same room, not two people pushing on the same door.
Principle 3: The combinations our material actually describes
Three, with their honest evidence attached:
| Combination | Rationale | Evidence |
|---|---|---|
| BPC-157 + TB-500 | Local repair + body-wide repair, as practitioners describe them | One 16-patient retrospective; one 2026 rat study |
| BPC-157 + DSIP | Recovery + sleep quality | Zero interaction data |
| GHK-Cu topical + any injectable | Topical stays local, minimal systemic interaction | Theoretical only |
Note the third row's reasoning. Topical GHK-Cu is the lowest-risk thing to add to any protocol, not because it has been tested alongside other compounds, but because a topical application does not enter systemic circulation in a meaningful way. That is mechanistic reasoning about why interaction is unlikely rather than evidence that it is absent, and the distinction is exactly the kind this course wants you making.
Principle 4: Do not stack these without medical guidance
Multiple growth-promoting peptides: amplified angiogenesis and proliferation signals, and therefore cancer risk.
Multiple GH-modulating peptides: unpredictable hormonal effects.
Any peptide plus CNS-active medications without physician awareness.
The ceiling
Maximum two peptides simultaneously for beginners.
Exceeding this multiplies unknowns beyond any reasonable risk assessment.
Claritide's Longevity Stack technically contains three compounds, and it flags this explicitly on the card: the argument for it is that GHK-Cu topical, cycled MOTS-C and short Epitalon courses run on separate schedules and rarely overlap fully. That is a caveat, not a permission slip.
The cost principle nobody mentions
Stacking costs scale linearly and benefits do not.
Two compounds is roughly double the vials, double the syringes, double the injections, and double the surface area for a contaminated or underdosed product to wreck your interpretation of the results.
The week 7–8 evaluation in the phase framework exists to ask whether the second compound actually earned that.